PharmaCielo has completed its second shipment of CBD Isolate to the Uruguayan subsidiary of a Latin American pharmaceutical company for additional pre-commercial testing.
Management commentary
Bill Petron, CEO of PharmaCielo, commented, "Our global business development team continues to make progress getting PharmaCielo's products into the hands of potential customers in new markets, and turning those early relationships into commercial deals. We continue to expect the next twelve months to be a period of significant growth and value creation for our shareholders as the team executes on the Company's growing sales pipeline."
For more information:
PharmaCielo
[email protected]
www.pharmacielo.com